Table 11.
Analysis of predictive factors for grade 1 or 2 late genitourinary toxicity
| Variables | 24-month actuarial rate of grade 1 or 2 late GU toxicity, % |
P-value
|
|
|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||
| Age, years, ≤70 versus >70 | 80.0 versus 83.3 | 0.642 | 0.836 |
| RT target, PG versus PG + SV versus PG + SV + PLN | 75.0 versus 83.3 versus 100 | 0.428 | 0.230 |
| Androgen-deprivation therapy, yes versus no | 100 versus 80.4 | 0.107 | 0.117 |
| Pretreatment GU symptoms, yes versus no | 87.2 versus 63.6 | 0.092 | 0.099 |
| Bladder | |||
| V5 ≤85% versus >85% | 73.1 versus 91.7 | 0.071 | 0.078 |
| V10 ≤75% versus >75% | 73.1 versus 91.7 | 0.100 | 0.108 |
| V20 ≤61% versus >61% | 72.0 versus 92.0 | 0.076 | 0.083 |
| V30 ≤44% versus >44% | 76.0 versus 88.0 | 0.334 | 0.346 |
| V40 ≤27% versus >27% | 76.9 versus 87.5 | 0.327 | 0.339 |
| V50 ≤15% versus >15% | 73.1 versus 91.7 | 0.081 | 0.089 |
| V60 ≤8% versus >8% | 74.1 versus 91.3 | 0.036 | 0.051 |
| V70 ≤3% versus >3% | 71.4 versus 95.5 | 0.024 | 0.030 |
| V75 ≤1% versus >1% | 73.1 versus 91.7 | 0.111 | 0.120 |
| Max dose ≤76.9 Gy versus >76.9 Gy | 72.0 versus 92.0 | 0.054 | 0.060 |
Abbreviations: RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GU, genitourinary; Max dose, maximum dose.